ABSTRACT

Zea mays L. (Poaceae), also known as purple corn, is an annual herbaceous plant that is grown as food for human consumption in a variety of forms, including cooking oils and sweeteners in processed food and beverage products. The purpose of this study was to determine whether a novel purple corn extract, FB801, might have an anti-atopic dermatitis (AD) effect on AD-like skin lesions induced by 2,4-dinitrochlorobenzene (DNCB) in BALB/c mice. Topical sensitization (1%) and challenge (0.3%) by DNCB were performed on the dorsal skin and right ear of BALB/c mice to induce AD. Following FB801 and dexamethasone administered orally, the severity of skin lesions was examined macroscopically and histologically. Serum levels of immunoglobulin E (IgE) and various cytokines were determined by enzyme-linked immunosorbent assay. Oral administration of FB801 significantly reduced typical symptoms of AD (erythema/bleeding, swelling, molting/erosion and scaling/drying), scratching frequencies, and the recruitment of inflammatory and mast cells. In addition, FB801 suppressed serum levels of IgE and T helper (Th)2 type cytokines such as interleukin (IL)-4 and IL-10 in DNCB-treated BALB/c mice. Furthermore, FB801 reduced the degradation of inhibitor of nuclear factor-κB proteins (NF-κB) in tumor necrosis factor (TNF)-α-stimulated human keratinocyte (HaCaT) cells. These results suggest that FB801 inhibited the development of the AD-like skin symptoms by regulating Th1 and Th2 responses in the skin lesions in mice and suppressing TNF-α induced NF-κB activation in HaCaT cells, suggesting that FB801 has potential application as an effective alternative therapy for the prevention and management of AD.

摘要

玉米（禾本科），也称为紫玉米，是一种一年生草本植物，以多种形式作为人类食用的食物种植，包括加工食品和饮料产品中的食用油和甜味剂。本研究的目的是确定新型紫玉米提取物 FB801 是否可能对 BALB/c 小鼠由 2,4-二硝基氯苯 (DNCB) 诱导的 AD 样皮肤损伤具有抗特应性皮炎 (AD) 作用。对 BALB/c 小鼠的背侧皮肤和右耳进行局部致敏（1%）和 DNCB 攻击（0.3%）以诱导 AD。口服 FB801 和地塞米松后，从肉眼和组织学角度检查皮肤损伤的严重程度。通过酶联免疫吸附测定测定血清免疫球蛋白E（IgE）和各种细胞因子的水平。口服 FB801 显着减少 AD 的典型症状（红斑/出血、肿胀、蜕皮/糜烂和鳞屑/干燥）、抓挠频率以及炎症和肥大细胞的募集。此外，FB801 抑制 DNCB 治疗的 BALB/c 小鼠中 IgE 和 T 辅助 (Th)2 型细胞因子（例如白细胞介素 (IL)-4 和 IL-10）的血清水平。此外，FB801 减少了肿瘤坏死因子 (TNF)-α 刺激的人角质形成细胞 (HaCaT) 细胞中核因子 -κB 蛋白抑制剂 (NF-κB) 的降解。这些结果表明，FB801通过调节小鼠皮损中的Th1和Th2反应以及抑制HaCaT细胞中TNF-α诱导的NF-κB活化来抑制AD样皮肤症状的发展，这表明FB801具有作为有效治疗AD样皮肤症状的潜在应用。预防和管理 AD 的替代疗法。